Intrinsiqq
Usana Health Sciences, Inc. logo

Usana Health Sciences, Inc. Financials

USNA

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 18 available years
Income Statement
TTM
JAN 2026
DEC 2024
DEC 2023
DEC 2022
JAN 2022
Revenues
Revenue$913$925$855$921$999$1,186
Cost of Revenue$206$201$161$177$194$218
Gross Profit$707$724$693$744$805$969
General & Administrative$335$337$263$257$262$279
Research & Development–$11$12$11$12$11
Total Operating Expenses$708$687$627$651$697$798
Operating Income-$1$37$66$93$108$170
Non-Operating
Net Interest Expense$2$2$11$9$4$2
Other Non-Operating Income (Expense)$2$3-$1$0-$3-$2
EBT (Earnings Before Tax)$3$42$76$102$109$171
Income Tax Expense$32$30$34$39$39$54
Net Income
Net Income-$22$11$42$64$69$117
Per Share Data
Revenue Per Share$49.41$49.81$44.59$47.61$51.71$58.32
EPS (Basic)-$1.18$0.58$2.20$3.31$3.60$5.78
EPS (Diluted)-$1.18$0.58$2.19$3.30$3.59$5.73
Weighted Avg Shares (Basic)18.5M18.5M19.1M19.3M19.3M20.1M
Weighted Avg Shares (Diluted)18.5M18.6M19.2M19.3M19.3M20.3M
Shares Outstanding18.5M18.6M19.2M19.3M19.3M20.3M

Usana Health Sciences (USNA) financials: revenue, profit and margins

Usana Health Sciences (USNA) generated about $913 million in revenue and -$22 million in net income (a -2.4% net margin) over the trailing twelve months, growing at roughly -4.0% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Usana Health Sciences's (USNA) revenue?+

Usana Health Sciences generated about $913 million in revenue over the trailing twelve months. Revenue has grown at roughly -4.0% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Usana Health Sciences profitable?+

Usana Health Sciences reported about -$22 million in net loss over the trailing twelve months, a net margin of roughly -2.4%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Usana Health Sciences's profit margins?+

Usana Health Sciences runs a gross margin of about 77.4%, an operating margin of about -0.1%, a net margin of about -2.4%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Usana Health Sciences growing?+

Usana Health Sciences's revenue has compounded at roughly -4.0% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside USNA's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 11 Aug 2026, covering the period ending 4 Jul 2026, as reported to the SEC. Data last refreshed 14 Aug 2026. How this is calculated.

Fiscal year ends Jan.

Peers

Medicinal Chemicals & Botanical Products · Pick stocks to compare with USNA

CompareIntrinsic value
TLRYTilray Brands, Inc.
$2.96+11.70%30
TCNNFTrulieve Cannabis Corp.
$11.60+0.52%36
AAWHAscend Wellness Holdings, Inc.
$0.40-0.74%11
CGCCanopy Growth Corporation
$0.75+6.36%25
JUSHFJushi Holdings Inc.
C$0.66-8.33%39
BTMDBiote Corp.
$1.23+9.38%53
CRONCronos Group Inc.
$3.51+3.85%81
MRMDMariMed Inc.
$0.06+25.83%35

Held by ETFs

USNA is in 18 US ETFs. The largest of them, with USNA's weight in each:

Spot a number that looks wrong? Check it in USNA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing USNA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.